drugset / Trial / NCT04791839
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Phase 2
Active not recruiting
30 enrolled
Washington University School of Medicine
Arcus Biosciences, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Since anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latter two have shown synergism in combination with antibodies against PD-1, othis study aims to evaluate the efficacy and tolerability of the triplet combination of zimberelimab, domvanalimab, and etrumadenant in patients with non-small cell lung cancer previously treated with immune checkpoint blockade therapy.
Timeline
- Start
- 2021-08-04
- Primary completion
- 2026-10-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Domvanalimab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Etrumadenant | Small molecule | 150 mg | Oral |
| Subject | Zimberelimab | Monoclonal antibody | 360 mg | Intravenous |